BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1210@pharmaconomics
DTSTAMP:20260707T023554Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:PHAR Phase 3 — napazimone (KL1333) (estimated date)
DESCRIPTION:Phase 3 trial results for napazimone (KL1333) in primary mitochondrial disease are due ~ Dec 31\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1828316/000182831626000008/a2025q4pressrelease.htm\n\nTrack it: https://www.pharmaconomics.com/e/1210
URL:https://www.pharmaconomics.com/e/1210
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PHAR catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR